BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19127942)

  • 1. The European paediatric initiative: 1 year of experience.
    Saint-Raymond A; Seigneuret N
    Paediatr Drugs; 2009; 11(1):9-10. PubMed ID: 19127942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of medicines for children in Europe: ethical implications.
    Saint Raymond A; Brasseur D
    Paediatr Respir Rev; 2005 Mar; 6(1):45-51. PubMed ID: 15698816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European paediatric legislation: benefits and perspectives.
    Rocchi F; Paolucci P; Ceci A; Rossi P
    Ital J Pediatr; 2010 Aug; 36():56. PubMed ID: 20716337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who are the PDCO?
    Dempsey EM; Connolly K
    Eur J Pediatr; 2014 Feb; 173(2):233-5. PubMed ID: 23925423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More medicines for children: impact of the EU paediatric regulation.
    Nordenmalm S; Tomasi P; Pallidis C
    Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation in children 10years after the European pediatric regulation current challenges and perspectives.
    Élie V; Leroux S; Kaguelidou F; Jacqz-Aigrain E
    Therapie; 2018 Apr; 73(2):113-117. PubMed ID: 29580612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation.
    Lindell-Osuagwu L; Hakkarainen M; Sepponen K; Vainio K; Naaranlahti T; Kokki H
    J Clin Pharm Ther; 2014 Apr; 39(2):144-53. PubMed ID: 24329556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications.
    Collier J
    Br J Clin Pharmacol; 1999 Jul; 48(1):5-8. PubMed ID: 10383552
    [No Abstract]   [Full Text] [Related]  

  • 10. Will children with cancer benefit from the new European Paediatric Medicines Regulation?
    Vassal G
    Eur J Cancer; 2009 Jun; 45(9):1535-46. PubMed ID: 19419857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Rocchi F; Tomasi P
    Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problems of drug testing in children in the United States.
    Yaffe SJ
    Pediatr Pharmacol (New York); 1983; 3(3-4):339-48. PubMed ID: 11659147
    [No Abstract]   [Full Text] [Related]  

  • 13. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EU's new paediatric medicines legislation: serving children's needs?
    Permanand G; Mossialos E; McKee M
    Arch Dis Child; 2007 Sep; 92(9):808-11. PubMed ID: 17715445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medicines for children and "off-label use" 5 years after implementation of the Paediatric Regulation (EC) No 1901/2006. An interim analyis].
    Afentaki A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Sep; 57(9):1111-9. PubMed ID: 25139386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
    Ceci A; Felisi M; Baiardi P; Bonifazi F; Catapano M; Giaquinto C; Nicolosi A; Sturkenboom M; Neubert A; Wong I
    Eur J Clin Pharmacol; 2006 Nov; 62(11):947-52. PubMed ID: 17021892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug prescription for hospitalized pediatric patients: how can the quality be evaluated?].
    Meiners MM; Bergsten-Mendes G
    Rev Assoc Med Bras (1992); 2001; 47(4):332-7. PubMed ID: 11813049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn].
    Riedel C; Lehmann B; Broich K; Sudhop T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Dec; 59(12):1587-1592. PubMed ID: 27778087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
    Winzenburg G
    Int J Pharm; 2014 Aug; 469(2):260-2. PubMed ID: 24704106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.